An isolation strategy for biomarkers that predict cancer relapse after 5-FU based adjuvant chemotherapy

被引：0
|
作者：
Nishizuka, Satoshi Stephen [1 ]
Ishida, Kazushige [2 ]
Uesugi, Noriyuki [1 ]
Chiba, Takehiro [1 ]
Matsuo, Teppei [1 ]
Yamada, Noriyuki [1 ]
Otsuka, Koki [1 ]
Koeda, Keisuke [1 ]
Sugai, Tamotsu [1 ]
Wakabayashi, Go [1 ]
机构：
[1] Iwate Med Univ, Sch Med, Morioka, Iwate 020, Japan
[2] NCI, Bethesda, MD 20892 USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.AM2011-4129
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4129
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Delayed start of adjuvant 5-FU/leucovorin based chemotherapy in colon cancer is safe up to 12 weeks postoperatively
    Carlsson, G.
    Albertsson, P.
    Gustavsson, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] Methotrexate (MTX) and 5-fluorouracil (5-FU) in advanced colorectal cancer patients previously treated with adjuvant 5-FU
    Pronzato, P
    Vaira, F
    Viganni, A
    Losardo, P
    Bertelli, G
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 760 - 760
  • [23] SIGNIFICANCE OF RELAPSE FOLLOWING ADJUVANT THERAPY WITH CMF OR 5-FU IN HIGH-RISK BREAST-CANCER
    CHLEBOWSKI, RT
    WEINER, JM
    LUCE, J
    HESTORFF, R
    LANG, JE
    REYNOLDS, R
    GODFREY, T
    RYDEN, VMJ
    BATEMAN, JR
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 146 - 146
  • [24] ADJUVANT CHEMOTHERAPY IN CANCER OF THE COLON AND RECTUM - DEMONSTRATION OF EFFECTIVENESS OF PROLONGED 5-FU CHEMOTHERAPY IN A PROSPECTIVELY CONTROLLED, RANDOMIZED TRIAL
    GRAGE, TB
    MOSS, SE
    SURGICAL CLINICS OF NORTH AMERICA, 1981, 61 (06) : 1321 - 1329
  • [25] Global clinical experience with adjuvant oxaliplatin/5-fluorouracil (5-FU)-based chemotherapy for colon cancer: ACCElox registry.
    Ji, J.
    Park, Y. S.
    Liu, M.
    Raafat, J.
    Szpak, W.
    Bouzid, K.
    Cornelio, G. H.
    Brenner, B.
    Ghosn, M.
    Zalcberg, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] 5-FU dose monitoring under neoadjuvant radiochemotherapy and adjuvant chemotherapy for locally advanced rectal cancer
    Conradi, L-C
    Quack, H.
    Sprenger, T.
    Wolff, H. A.
    Binder, L.
    Ghadimi, B. M.
    Homayounfar, K.
    Bleckmann, A.
    Lorenzen, S.
    Nietert, M.
    Beissbarth, T.
    Liersch, T.
    ONKOLOGIE, 2013, 36 : 73 - 73
  • [27] The results of a systemic chemotherapy with cisplatin, 5-FU and folinic acid in adjuvant therapy by resected gastric cancer
    Ridwelski, K
    Fahlke, J
    Gebauer, T
    Lippert, H
    PROGRESS IN GASTRIC CANCER RESEARCH 1997: PROCEEDINGS OF THE 2ND INTERNATIONAL GASTRIC CANCER CONGRESS, 1997, : 1489 - 1493
  • [28] CHEMOTHERAPY FOR COLORECTAL-CANCER WITH A COMBINATION OF PALA AND 5-FU
    BEDIKIAN, AY
    STROEHLEIN, JR
    KARLIN, DA
    BENNETTS, RW
    BODEY, GP
    VALDIVIESO, M
    CANCER TREATMENT REPORTS, 1981, 65 (9-10): : 747 - 753
  • [29] Adjuvant 5-FU/cisplatin and chemoradiation with capecitabine after radical gastrectomy for advanced gastric cancer
    Lee, H.
    Choi, Y.
    Hur, W.
    Kwon, H.
    Kim, M.
    Jung, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S303 - S304
  • [30] Impact of reduced dose intensity of adjuvant bolus 5-FU based chemotherapy for stage 2 and 3 colon cancer.
    Yu, S
    O'Reilly, S
    Gill, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 286S - 286S
12345